Brought to you by 
Proteostasis licenses CF candidates from Scripps Research Institute
21 Apr 2021
Executive Summary
Proteostasis Therapeutics Inc. (PTI; drug candidates that maintain protein stability) has licensed exclusive rights to small-molecule modulators of protein folding and trafficking in cystic fibrosis. These are agents arising from existing work already being performed by Scripps Research Institute.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Proteostasis licenses CF candidates from Scripps Research Institute
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice